RVRC
Revium Rx.$1.43 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $1.43
1 year
+175.0%
from $0.5200 · Oct 28
30 days
0.0%
from $1.43
52-week range
$0.5200–1.67
−14% from high · low Oct 28
Avg volume 20D
0
Sep 29 spike 0
Filing reports
2
analyzed by SecBot
SecBot read MIXED 2 reports · latest
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2
Price
Daily candles with volume.
No data for this timeframe.
Signal stack
Where each data set points today.
- TrendRANGE
1% below its 50-day average.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Jun 1, 2026 SEC Apr 20, 2026 SEC
Revium Rx. announced the resignation of CFO Arie Gordashnikov effective May 27, 2026, with no reported disagreement…
8-K · Impact 2/10
Revium Rx appointed Amir Avraham as permanent CEO effective February 1, 2026, and Shlomi Schwartzblat as a director…
8-K · Impact 3/10
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
SecBot reports
2 filings · 0 bullish · 0 bearish · 2 neutral- NEUTRAL 8-KJun 1, 2026
Revium Rx. announced the resignation of CFO Arie Gordashnikov effective May 27, 2026, with no…
This is a routine CFO transition with an experienced replacement. Monitor for any strategic or financial changes in subsequent filings, but no immediate trading action warranted.
- NEUTRAL 8-KApr 20, 2026
Revium Rx appointed Amir Avraham as permanent CEO effective February 1, 2026, and Shlomi…
Monitor for future funding announcements as the $50,000 bonus is tied to raising $5M in equity investments within 18 months; watch for potential share dilution from the 1.9 million stock options…
All RVRC filing & press-release reports (2)
- 8-K reportJun 1, 2026
- 8-K reportApr 20, 2026